李宁,陈松杰,陈彦纯,杨伦,王永峰

• 1:珠海津之敦医药科技有限公司
• 2:吉林大学珠海学院化学与药学系

摘要(Abstract)：

本文通过查阅、分析近年来国内外医药学期刊报道的文献资料,对聚季铵盐-1和苯扎氯铵2种抑菌剂在眼用制剂中的应用范围、抑菌效力、眼部毒性刺激性、临床研究等进行综述,为眼用制剂的研发中抑菌剂的合理使用,以及减少抑菌剂可能导致的不良反应提供参考。

关键词(KeyWords)： 抑菌剂;聚季铵盐-1;苯扎氯铵;曲伏前列素

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李宁,陈松杰,陈彦纯,杨伦,王永峰

参考文献(References)：

• [1]宁黎丽.眼用制剂研发过程中应关注抑菌剂的合理使用和质量控制[J].中国药学杂志,2007,42(23):1836-1838.
• [2]Freeman PD,Kahook MY.Preservatives in Topical Ophthalmic Medications:Historical and Clinical Perspectives[J].Expert Rev Ophthalmol,2009,4(1):59-64.
• [3]Paimela T,Ryhnen T,Kauppinen A,et al.The preservative polyquaternium-1 increases cytoxicity and NFkappa B linked inflammation in human corneal epithelial cells[J].Molecular Vision,2012,18(1):1189-1196.
• [4]Kaur IP,Lal S,Rana C,et al.Ocular preservatives:associated risks and newer options[J].Cutaneous and Ocular Toxicology,2009,28(3):93-103.
• [5]Morrissey I,Oggioni MR,Knight D,et al.Evaluation of Epidemiological Cut-Off Values Indicates that Biocide Resistant Subpopulations Are Uncommon in Natural Isolates of ClinicallyRelevant Microorganisms[J].Plos one,2014,9(1):1-10.
• [6]贾瑞.聚季铵盐-1作为眼用制剂抑菌剂的应用研究[D].山东:山东大学药学院,2013.
• [7]Brasnu E,Brignole-Baudouin F,Riancho L,et al.In Vitro Effects of Preservative-Free Tafluprost and Preserved Latanoprost,Travoprost,and Bimatoprost in a Conjunctival Epithelial Cell Line[J].Curr Eye Res,2008,33(4):303-312.
• [8]Liang H,Pauly A,Riancho L,et al.Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system[J].Br J Ophthalmol,2011,95(6):869-975.
• [9]Pellinen P,Huhtala A,Tolonen A,et al.The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo[J].Curr Eye Res,2012,37(2):145-154.
• [10]Ammar DA,Kahook MY.Effects of benzalkonium chloride-or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells[J].Molecular Vision,2011,17(1):1806-1813.
• [11]Ammar DA,Noecker RJ,Kahook MY.Effects of Benzalkonium Chloride-and Polyquad-Preserved Combination Glaucoma Medications on Cultured Human Ocular Surface Cells[J].Adv Ther,2011,28(6):501-510.
• [12]Baudouin C,Riancho L,Warnet JM,et al.In vitro studies of antiglaucomatous prostaglandin analogues:travoprost with and without benzalkonium chloride and preserved latanoprost[J].Invest Ophthalmol Vis Sci,2007,48(9):4123-4128.
• [13]Brignole-Baudouin F,Riancho L,Liang H,et al.Comparative in vitro toxicology study of travoprost polyquad-preserved,travoprost BAK-preserved,and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells[J].Curr Eye Res,2011,36(11):979-988.
• [14]Baudouin C,LabbéA,Liang H,et al.Preservatives in eyedrops:the good,the bad and the ugly[J].Prog Retin Eye Res,2010,29(4):312-334.
• [15]Tu EY.Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives[J].Saudi J Ophthalmol,2014,28(3):182-187.
• [16]Khoh-Reiter S,Jessen BA.Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model[J].BMC Ophthalmology,2009,9(1):5-6.
• [17]Noecker R,Miller KV.Benzalkonium Chloride in Glaucoma Medications[J].The Ocular Surface,2011,9(3):159-162.
• [18]Inoue K,Iwasa M,Wakakura M,et al.Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma[J].Clin Ophthalmol,2012,6(1):1315-1319.
• [19]Henry JC,Peace JH,Stewart JA,et al.Efficacy,safety,and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy[J].Clin Ophthalmol,2008,2(3):613-621.
• [20]Lewis RA,Katz GJ,Weiss MJ,et al.Travoprost 0.004%with and without benzalkonium chloride:a comparison of safety and efficacy[J].J Glaucoma,2007,16(1):98-103.
• [21]Tressler CS,Beatty R,Lemp MA.Preservative Use in Topical Glaucoma Medications[J].The Ocular Surface,2011,9(3):140-158.
• [22]Kitazawa Y,Smith P,Sasaki N,et al.Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride:a prospective,randomized,doubled-masked comparison of safety and efficacy[J].Eye(Lond),2011,25(9):1161-1169.
• [23]Swymer C,Neville MW.Tafluprost:the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension[J].Ann Pharmacother,2012,46(11):1506-1510.